Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $4.3 million.

  • Lexaria Bioscience's Cash & Equivalents fell 4700.3% to $4.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $4.3 million, marking a year-over-year decrease of 4700.3%. This contributed to the annual value of $1.8 million for FY2025, which is 7227.45% down from last year.
  • Lexaria Bioscience's Cash & Equivalents amounted to $4.3 million in Q4 2025, which was down 4700.3% from $1.8 million recorded in Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's Cash & Equivalents peaked at $10.9 million during Q3 2021, and registered a low of $1.4 million during Q3 2023.
  • Over the past 5 years, Lexaria Bioscience's median Cash & Equivalents value was $6.1 million (recorded in 2022), while the average stood at $6.0 million.
  • In the last 5 years, Lexaria Bioscience's Cash & Equivalents surged by 197484.28% in 2021 and then plummeted by 7674.09% in 2023.
  • Over the past 5 years, Lexaria Bioscience's Cash & Equivalents (Quarter) stood at $10.9 million in 2021, then tumbled by 58.41% to $4.5 million in 2022, then plummeted by 56.89% to $2.0 million in 2023, then soared by 313.39% to $8.1 million in 2024, then crashed by 47.0% to $4.3 million in 2025.
  • Its Cash & Equivalents was $4.3 million in Q4 2025, compared to $1.8 million in Q3 2025 and $4.6 million in Q2 2025.